← All trials
NCT05382091
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2023
- Primary completion
- Mar 1, 2025
- Completion date
- Mar 1, 2026
- First posted
- May 19, 2022
- Last posted
- Dec 9, 2022
- Enrollment
- 250
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Go Medical Industries Pty LtdLead sponsor
- The EMMES CorporationCollaborator
- National Institute on Drug Abuse (NIDA)Collaborator
- University at BuffaloCollaborator
- Columbia UniversityCollaborator
- Columbia UniversityCollaborator
- Columbia UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.